Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer

Inclusion Criteria:

• Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma

• >= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and / orPARPi, at primary setting

• Platinum-free interval should be >=6 months from the last dose of platinum-basedchemotherapy

• Upfront SCR not feasible

• Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0to 2 within 28 days prior to recruitment.

• Patients must have adequate bone marrow, renal, hepatic and neurological functionwithin 28 days prior to the start of treatment.

Exclusion Criteria:

• Non-epithelial or borderline tumors are excluded

• Patients who have with concurrent malignancy within five years (except for basal orsquamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioidendometrial carcinoma without lymphovascular invasion) are excluded.

• Patients using more than one line of chemotherapy are excluded.

• Patients who have platinum-resistant or refractory recurrence are excluded.

• Patients having second relapse or beyond are excluded.

• Patients who have contraindications to operation, e.g., unresolved thrombocytopenia,bowel obstruction in the last 4 weeks prior to enrolment